WHAT IS CLAIMED IS:

1. A bispecific ribonucleic acid (RNA) aptamer comprising Formula I:

X_1-(aptamer 1)-X_2-(linker)-Y_1-(aptamer 2)-Y_2-invdT

Formula I

wherein aptamer 1 is selected from the group consisting of SEQ ID. Nos.: 1-46 and 67 or at least one nucleotide sequence having at least about 70% identity thereto and wherein aptamer 2 is selected from the group consisting of SEQ ID. Nos: 47-48 or at least one nucleotide sequence having at least about 70% identity thereto, wherein the order of aptamer 1 and aptamer 2 can be varied.

2. The bispecific RNA aptamer of claim 1, wherein the linker is a nucleotide linker comprising five or more 2' O-methyl (2'OMe) uridine (U) residues.

3. The bispecific RNA aptamer of claim 1, wherein the linker is a non-nucleotide linker selected from the group consisting of 1,3-propanediol, 1,6 hexanediol, 1,12 dodecyldiol, triethylene glycol and hexaethylene glycol.

4. The bispecific RNA aptamer of claim 1, wherein one or more nucleotides of the bispecific RNA aptamer are chemically modified.

5. The bispecific RNA aptamer of claim 4, wherein the one or more chemically modified nucleotides are selected from the group consisting of 2'Fluoro (2'F) Guanosine, 2' OMe Guanosine, 2'OMe Adenosine, 2'OMe Cytosine, 2'OMe Uridine and combinations thereof.

6. The bispecific RNA aptamer of claim 1, wherein the bispecific RNA aptamer specifically binds to Vascular Endothelial Growth Factor (VEGF) or an isoform thereof and Interleukin 8 (IL8).

7. The bispecific RNA aptamer of claim 6, wherein the bispecific RNA aptamer inhibits the function of VEGF or an isoform thereof and IL8 by an amount between about 90% and about 100%.

8. The bispecific RNA aptamer of any one of claims 1-7, wherein the bispecific RNA aptamer is attached directly to polyethylene glycol (PEG).

9. The bispecific RNA aptamer of claim 8, wherein the bispecific RNA aptamer has a hydrodynamic radius greater than about 10 nm.

10. A pharmaceutical composition comprising the bispecific RNA aptamer of any one of claims 1-9 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, formulated for intravitreal administration.

12. Use of the bispecific RNA aptamer of any one of claims 1-9 or the pharmaceutical composition of claim 10 or 11 in the manufacture of a medicament for treating a retinal disease or disorder in a subject in need thereof.

13. The use of claim 12, wherein the retinal disease or disorder is selected from the group consisting of the wet form of age-related macular degeneration (wAMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, retinopathy of prematurity and radiation retinopathy

14. The use of claim 12 or 13, wherein the subject in need thereof has been previously treated with one or more anti-VEGF agents, but where the subject has shown a suboptimal response to such treatment.

15. The use of any one of claims 12-14, wherein the medicament is for intravitreal injection.